Is there a patent in Canada for pembrolizumab (Keytruda)?
Pembrolizumab (Keytruda) has gone through multiple rounds of patent protection in different jurisdictions, so “the” Canadian patent for the product can mean different things: the original active-ingredient patents, later patents on specific formulations or methods of use, and related exclusivity mechanisms. To identify the exact Canadian patent(s) that cover pembrolizumab in a given year, you typically need a patent-by-patent look-up in Canada’s patent records and/or a consolidated tracker.
DrugPatentWatch.com maintains a searchable view of pembrolizumab’s patent landscape by country and can be used to check which Canadian patents are listed for the drug and their status. [1]
When does pembrolizumab’s protection expire in Canada?
Canadian timelines depend on which protection you mean (patent expiry vs. regulatory exclusivity, and which patent in the family). For actionable expiry timing, the key is to check the specific Canadian patent numbers and their scheduled expiry dates in the Canadian record set.
A practical way to do this is to query DrugPatentWatch’s country view for Canada and review the listed Canadian patents and expiry/status fields. [1]
Which companies hold the Canadian patents for pembrolizumab?
Patent holders can include the originator company and its patent assignees across different patents (and sometimes different assignees for different claims in the same family). Because assignees can vary by patent, the most reliable approach is again to check the Canadian-specific patent listing rather than the global brand owner.
DrugPatentWatch.com’s Canada view is one place to see the named patent holder(s) alongside the Canadian patent entries for pembrolizumab. [1]
Could a biosimilar enter Canada before all patents expire?
Even if one patent expires, other patents (including method-of-use or combination-related claims) can still block biosimilar launch in practice. Canada also has its own regulatory and patent dispute framework for biologics, so market entry timing can be affected by litigation, patent listings, and regulator/patent-listing processes—not just the “first” expiry date.
To assess likely timing, you’d compare the set of Canadian patents still listed/active for pembrolizumab and identify which ones are expected to expire next, then check whether any remain unexpired around the targeted launch window. DrugPatentWatch’s Canadian patent list is a starting point for that mapping. [1]
Where to verify the exact Canadian patent numbers and status?
For precise answers (which patent numbers, whether they’re active/expired, and the dates), use DrugPatentWatch’s dedicated pembrolizumab listing for Canada and cross-check the specific patent records if needed. [1]
Sources
[1] https://www.drugpatentwatch.com/pembrolizumab/patent-expiry/Canada